BeNeLuxBelgiumNetherlandsLuxembourg

Co-existence: 25 metres sufficient

16.05.2007

Wageningen – A Dutch analysis has concluded that the country’s forseen GMO regulations for coexistance are efficient. A preliminary analysis of the two-year program carried out by the University of Wageningen and the Institute for Food Safety has shown that a 25-metre isolation distance is sufficient to avoid labeling obligations for farmers with conventional or organic maize in the neighbourhood of GM maize cultivations. The researchers found that the distance led to an average content of 0.01% to 0.3% of insect-resistant Bt-maize (MON810) in the non-GM crops. At a distance of 250 metres, the average outcrossing rate lays between 0% and 0.003%. Accordingly, all measured rates remained far below the EU labeling threshold of 0.9%.Another part of the Dutch coexistance agreement was a risk analysis with an evaluation of potential economical damages to conventional or organic farmers caused by the cultivation of GM crops in the Netherlands. This study was conducted by the Institute for Risk Management in Agriculture at the University of Wageningen and comprises damage scenarios for maize, potatoes and sugar beet. According to the scientists, the analysis reveals that the value for the average direct economic damage as a consequence of cross breeding is almost zero.

BeNeLuxBelgiumNetherlandsLuxembourg

16.12.2011

Mechelen - Galapagos NV confirms its status as one of Europe best drug discovery companies. The Belgian biotech received €4 million as the first milestone payments from French Servier for the discovery of new targets for...

BeNeLuxBelgiumNetherlandsLuxembourg

15.12.2011

Munich/Groningen/Penzberg – For ten years, the application of image-guided surgery with tumour-specific fluorescent dyes has been limited to animal studies, because no one could predict safety or bio­distribution of such targeted...

BeNeLuxBelgiumNetherlandsLuxembourg

02.12.2011

Zwijnaarde/Rotterdam – In vivo camelid antibody specialist arGEN-X BVBA has baged €27.5 million of fresh capital for development of its preclinical monoclonal antibody pipeline. The round B financing of the 3 year-old company,...

BeNeLuxBelgiumNetherlandsLuxembourg

28.11.2011

Brussels/Ghent – Belgian researchers have demonstrated that tumour cells secrete the angiogenesis factor VEGF to create a microenvironment that fosters proliferation of cancer stem cells. In mice with squamous cell carcinoma,...

BeNeLuxBelgiumNetherlandsLuxembourg

23.11.2011

Mechelen – Belgian drugmaker Galapagos NV has reported impressive results of a proof-of-concept trial with its oral janus kinase 1 blocker GLPG0634 + Methothrexate in patients with active rheumatoid arthritis. In the 24 patients...

BeNeLuxBelgiumNetherlandsLuxembourg

18.11.2011

Naarden – Enzyme replacement therapies specialist Oxyrane NV raised €20 million in a series D round of financing. The therapies are designed to treat lysosomal storage diseases, a class of more than forty rare inherited diseases....

BeNeLuxBelgiumNetherlandsLuxembourg

14.11.2011

Hilden/Venlo – Sample and assay technologies provider Qiagen N.V. is set to eliminate about 10% of its current global workforce of 3,800 employees. The company says the cuts are one result of implementing a project aimed at...

BeNeLuxBelgiumNetherlandsLuxembourg

09.11.2011

New York/Ghent - Big brother is gone. Belgian biotech Ablynx regained the rights for nanobodies targeting TNF-alpha from Pfizer. The US- pharma outfit decided it did't want ATN-103, even though it met its goal in a mid-stage...

BeNeLuxBelgiumNetherlandsLuxembourg

25.10.2011

Amsterdam - The second blow could be the ultimate one. Amsterdam Molecular Therapeutics received a second negative opinion for Glybera to treat lipoprotein lipase (LPL) deficiency. The European Medicines Agency's (EMA) Committee...

BeNeLuxBelgiumNetherlandsLuxembourg

13.10.2011

Bilthoven – The current impact of hospital acquired infections with multi-resistant bugs is lower than suggested by startling news articles. According to a study of Dutch researchers, bloodstream infections caused by...

Displaying results 11 to 20 out of 304

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-benelux/browse/1/article/co-existence-25-metres-sufficient.html

Stock list

All quotes

TOP

  • MAGFORCE (D)5.90 EUR9.26%
  • ABCAM (UK)387.00 GBP7.72%
  • NANOBIOTIX (F)17.40 EUR7.27%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • NOVACYT (F)4.40 EUR-8.33%

TOP

  • WILEX (D)3.12 EUR300.0%
  • SANTHERA (CH)69.30 CHF103.8%
  • ADDEX (CH)4.07 CHF82.5%

FLOP

  • MERCK KGAA (D)63.71 EUR-50.0%
  • HYBRIGENICS (F)1.72 EUR-34.4%
  • PROSENSA (NL)9.24 USD-24.4%

TOP

  • SANTHERA (CH)69.30 CHF3453.8%
  • GW PHARMACEUTICALS (UK)438.00 GBP800.9%
  • PAION (D)2.80 EUR311.8%

FLOP

  • CYTOS (CH)0.25 CHF-92.6%
  • EVOCUTIS (UK)0.21 GBP-92.1%
  • THROMBOGENICS (B)8.87 EUR-71.8%

No liability assumed, Date: 23.07.2014


Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events